HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen
Preclinical studies in disease-relevant models demonstrate the ability of HERVolution's HERV-targeting platform to control weight gain, reverse type 2 diabetes, and lower "inflammaging" biomarkers Exclusive license agreement, combined with core company-owned IP, further solidifies the...
Preclinical studies in disease-relevant models demonstrate the ability of HERVolution's HERV-targeting platform to control weight gain, reverse type 2 diabetes, and lower "inflammaging" biomarkers Exclusive license agreement, combined with core company-owned IP, further solidifies the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.